Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Slims down for Maintainable Weight reduction - 2'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- 3Israel and Lebanon's Hezbollah continue to trade attacks
- 4France's Senate backs ban on social media platforms for under-15s
- 5One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- UN panel says Israel operating 'de facto policy of torture'
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- Don’t let food poisoning crash your Thanksgiving dinner
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- Which Startup's Innovation Could Reform Medical care?
- Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- Iran steps up executions as experts warn state killing being used to suppress political dissent
- 100 new alien worlds: Scientists find hidden haul in data from NASA exoplanet-hunting spacecraft
- What is the Insurrection Act? Can Trump really use the military to 'put an end' to Minneapolis ICE protests?
